{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T12:14:29Z","timestamp":1782476069960,"version":"3.54.5"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T00:00:00Z","timestamp":1598400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004586","name":"Funda\u00e7\u00e3o Carlos Chagas Filho de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.02173","type":"journal-article","created":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T05:28:16Z","timestamp":1598419696000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["What Would Jenner and Pasteur Have Done About COVID-19 Coronavirus? The Urges of a Vaccinologist"],"prefix":"10.3389","volume":"11","author":[{"given":"Clarisa B.","family":"Palatnik-de-Sousa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,8,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"824","DOI":"10.4161\/hv.10295","article-title":"Smallpox vaccines: new formulations and revised strategies for vaccination","volume":"5","author":"Paran","year":"2009","journal-title":"Hum Vaccin."},{"key":"B2","unstructured":"Smallpox: Variolation2002"},{"key":"B3","doi-asserted-by":"publisher","first-page":"260","DOI":"10.3109\/08830185.2015.1082177","article-title":"Anti-infectious human vaccination in historical perspective","volume":"35","author":"D'Amelio","year":"2016","journal-title":"Int Rev Immunol."},{"key":"B4","unstructured":"RoyJ\n          Ann Illustrated History of Smallpox and its Eradication.2010"},{"key":"B5","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/nri3694","article-title":"From empiricism to rational design: a personal perspective of the evolution of vaccine development","volume":"14","author":"De Gregorio","year":"2014","journal-title":"Nat Rev Immunol."},{"key":"B6","unstructured":"De Oliveira SantosNS\n            RomanosMTV\n            WiggMD\n          Livro\u2013Introdu\u00e7\u00e3o \u00c0 Virologia Humana2002"},{"key":"B7","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3389\/fimmu.2020.00204","article-title":"The delay in the licensing of protozoal vaccines: a comparative history","volume":"11","author":"Palatnik-de-Sousa","year":"2020","journal-title":"Front Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S0140-6736(19)31279-6","article-title":"The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study","volume":"394","author":"Van Damme","year":"2019","journal-title":"Lancet."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e02287","DOI":"10.1128\/mBio.02287-18","article-title":"Development of thermostable lyophilized sabin inactivated poliovirus vaccine","volume":"9","author":"Shin","year":"2018","journal-title":"mBio."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1056\/NEJMoa0910074","article-title":"Implications of a circulating vaccine-derived poliovirus in Nigeria","volume":"362","author":"Jenkins","year":"2010","journal-title":"N Engl J Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S1286-4579(03)00075-3","article-title":"Louis pasteur (1822\u20131895)","volume":"5","author":"Bordenave","year":"2003","journal-title":"Microbes Infect."},{"key":"B12","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3390\/v8110279","article-title":"Rabies control and treatment: from prophylaxis to strategies with curative potential","volume":"8","author":"Zhu","year":"2016","journal-title":"Viruses."},{"key":"B13","doi-asserted-by":"publisher","first-page":"4518163","DOI":"10.1155\/2019\/4518163","article-title":"Evaluation of different stabilizers and inactivating compounds for the enhancement of vero cell rabies vaccine stability and immunogenicity: in vitro study","volume":"2019","author":"Olayan","year":"2019","journal-title":"BioMed Res Int."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e0128785","DOI":"10.1371\/journal.pone.0128785","article-title":"Intranasal immunization with pressure inactivated avian influenza elicits cellular and humoral responses in mice","volume":"10","author":"Barroso","year":"2015","journal-title":"PloS ONE."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e2074","DOI":"10.1002\/rmv.2074","article-title":"Inactivation methods for whole influenza vaccine production","volume":"29","author":"Sabbaghi","year":"2019","journal-title":"Rev Med Virol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e5538","DOI":"10.1371\/journal.pone.0005538","article-title":"Vaccination against human influenza A\/H3N2 virus prevents the induction of heterosubtypic immunity against lethal infection with avian influenza A\/H5N1 virus","volume":"4","author":"Bodewes","year":"2009","journal-title":"PloS ONE."},{"key":"B17","first-page":"131","article-title":"Toward a modern synthesis of immunity: Charles A. Janeway Jr. and the immunologist's dirty little secret","volume":"84","author":"Gayed","year":"2011","journal-title":"Yale J Biol Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/nrd1176","article-title":"Recent advances in the discovery and delivery of vaccine adjuvants","volume":"2","author":"O'Hagan","year":"2003","journal-title":"Nat Rev Drug Discov."},{"key":"B19","doi-asserted-by":"publisher","first-page":"104260","DOI":"10.1016\/j.meegid.2020.104260","article-title":"Genetic diversity and evolution of SARS-CoV-2","volume":"81","author":"Phan","year":"2020","journal-title":"Infect Genet Evol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e50366","DOI":"10.1371\/journal.pone.0050366","article-title":"Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing","volume":"7","author":"Elshabrawy","year":"2012","journal-title":"PloS ONE."},{"key":"B21","doi-asserted-by":"publisher","first-page":"255","DOI":"10.4103\/ijmr.IJMR_1058_20","article-title":"Genomic analysis of SARS-CoV-2 strains among Indians returning from Italy, Iran & China, & Italian tourists in India","volume":"151","author":"Potdar","year":"2020","journal-title":"Indian J Med Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1002\/jmv.25976","article-title":"SARS-CoV-2: structural diversity, phylogeny, and potential animal host identification of spike glycoprotein","volume":"92","author":"Dabravolski","year":"2020","journal-title":"J Med Virol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1038\/s41467-020-16638-2","article-title":"Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients","volume":"11","author":"Poh","year":"2020","journal-title":"Nat Commun."},{"key":"B24","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1080\/22221751.2020.1756700","article-title":"Attenuated SARS-CoV-2 variants with deletions at the S1\/S2 junction","volume":"9","author":"Lau","year":"2020","journal-title":"Emerg Microbes Infect."},{"key":"B25","doi-asserted-by":"publisher","first-page":"ciaa325","DOI":"10.1093\/cid\/ciaa325","article-title":"Simulation of the clinical and pathological manifestations of Coronavirus disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility","author":"Chan","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41591-020-0820-9","article-title":"The proximal origin of SARS-CoV-2","volume":"26","author":"Andersen","year":"2020","journal-title":"Nat Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1016\/j.vaccine.2008.07.029","article-title":"Immunogenicity assay of the leishmune vaccine against canine visceral leishmaniasis in Brazil","volume":"26","author":"Borja-Cabrera","year":"2008","journal-title":"Vaccine."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1038\/cti.2015.6","article-title":"From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE","volume":"4","author":"Coler","year":"2015","journal-title":"Clin Transl Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1007\/s00262-004-0598-5","article-title":"Thomsen-friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer","volume":"54","author":"Slovin","year":"2005","journal-title":"Cancer Immunol Immunother"},{"key":"B30","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1093\/cid\/ciu954","article-title":"Vaccines against malaria","volume":"60","author":"Ouattara","year":"2015","journal-title":"Clin Infect Dis"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1093\/infdis\/jiy095","article-title":"Immune responses to a recombinant glycoprotein e herpes zoster vaccine in adults aged 50 years or older","volume":"217","author":"Cunningham","year":"2018","journal-title":"J Infect Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1016\/S0264-410X(00)00415-1","article-title":"QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans","volume":"19","author":"Evans","year":"2001","journal-title":"Vaccine."},{"key":"B33","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1099\/vir.0.008169-0","article-title":"Smallpox virus plaque phenotypes: genetic, geographical and case fatality relationships","volume":"90","author":"Olson","year":"2009","journal-title":"J Gen Virol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"569","DOI":"10.20506\/rst.37.2.2825","article-title":"Rabies: a medical perspective","volume":"37","author":"Jackson","year":"2018","journal-title":"Rev Sci Tech."},{"key":"B35","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/d41573-020-00073-5","article-title":"The COVID-19 vaccine development landscape","volume":"19","author":"Thanh Le","year":"2020","journal-title":"Nat Rev Drug Discov."},{"key":"B36","unstructured":"Draft Landscape of COVID-19 Candidate Vaccines.2020"},{"key":"B37","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1126\/science.abb8923","article-title":"Rapid COVID-19 vaccine development","volume":"368","author":"Graham","year":"2020","journal-title":"Science."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(20)30763-7","article-title":"Ensuring global access to COVID-19 vaccines","volume":"395","author":"Yamey","year":"2020","journal-title":"Lancet."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1101\/2020.05.13.093195","article-title":"ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques","author":"van Doremalen","year":"2020","journal-title":"BioRxiv [Preprint]."},{"key":"B40","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1126\/science.abc1932","article-title":"Rapid development of an inactivated vaccine candidate for SARS-CoV-2","volume":"369","author":"Gao","year":"2020","journal-title":"Science."},{"key":"B41","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.autrev.2015.05.014","article-title":"On vaccine's adjuvants and autoimmunity: current evidence and future perspectives","volume":"14","author":"Pellegrino","year":"2015","journal-title":"Autoimmun Rev."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e40385","DOI":"10.1371\/journal.pone.0040385","article-title":"A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity","volume":"7","author":"Dicks","year":"2012","journal-title":"PloS ONE."},{"key":"B43","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/d41586-020-01092-3","article-title":"Coronavirus vaccine trials have delivered their first results\u2013but their promise is still unclear","volume":"581","author":"Callaway","year":"2020","journal-title":"Nature."},{"key":"B44","unstructured":"China's Sinovac Plots Pivotal COVID-19 Vaccine Trial in Brazil After Positive Phase 22020"},{"key":"B45","unstructured":"Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals.2020"},{"key":"B46","doi-asserted-by":"publisher","first-page":"6589","DOI":"10.1016\/j.vaccine.2009.08.032","article-title":"Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months","volume":"27","author":"King","year":"2009","journal-title":"Vaccine."},{"key":"B47","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2\u2013preliminary report","author":"Jackson","year":"2020","journal-title":"N Engl J Med."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1101\/2020.06.30.20142570","article-title":"Phase 1\/2 study to describe the safety and immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults 18 to 55 years of age: interim report","author":"Mulligan","year":"2020","journal-title":"medRxiv [Preprint]."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1101\/2020.07.17.20140533","article-title":"Concurrent human antibody and TH1 type T-cell responses elicited by a COVID-19 RNA vaccine","author":"Sahin","year":"2020","journal-title":"medRxiv [Preprint]."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.3201\/1107.050219","article-title":"SARS vaccine development","volume":"11","author":"Jiang","year":"2005","journal-title":"Emerg Infect Dis."},{"key":"B53","doi-asserted-by":"publisher","first-page":"4783","DOI":"10.1016\/j.vaccine.2020.05.064","article-title":"Consensus summary report for CEPI\/BC March 12-13, 2020 meeting: assessment of risk of disease enhancement with COVID-19 vaccines","volume":"38","author":"Lambert","year":"2020","journal-title":"Vaccine."},{"key":"B54","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/1348-0421.12754","article-title":"Gold nanoparticle-adjuvanted S protein induces a strong antigen-specific IgG response against severe acute respiratory syndrome-related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs","volume":"64","author":"Sekimukai","year":"2020","journal-title":"Microbiol Immunol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"123158","DOI":"10.1172\/jci.insight.123158","article-title":"Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection","volume":"4","author":"Liu","year":"2019","journal-title":"JCI Insight."},{"key":"B56","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1080\/21645515.2016.1177688","article-title":"Immunization with inactivated middle east respiratory syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus","volume":"12","author":"Agrawal","year":"2016","journal-title":"Hum Vaccines Immunother."},{"key":"B57","doi-asserted-by":"publisher","first-page":"12201","DOI":"10.1128\/JVI.06048-11","article-title":"A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge","volume":"85","author":"Bolles","year":"2011","journal-title":"J Virol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1021\/acsinfecdis.6b00006","article-title":"Immunodominant SARS coronavirus epitopes in humans elicited both enhancing and neutralizing effects on infection in non-human primates","volume":"2","author":"Wang","year":"2016","journal-title":"ACS Infect Dis."},{"key":"B59","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.vaccine.2005.08.055","article-title":"A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses","volume":"24","author":"Spruth","year":"2006","journal-title":"Vaccine."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.vaccine.2005.06.038","article-title":"Immunogenicity and protective efficacy in monkeys of purified inactivated vero-cell SARS vaccine","volume":"24","author":"Qin","year":"2006","journal-title":"Vaccine."},{"key":"B61","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1089\/vim.2010.0028","article-title":"Immunogenicity and protective efficacy in mice and hamsters of a \u03b2-propiolactone inactivated whole virus SARS-CoV vaccine","volume":"23","author":"Roberts","year":"2010","journal-title":"Viral Immunol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"152905","DOI":"10.1016\/j.phymed.2019.152905","article-title":"Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: a review","volume":"60","author":"Lacaille-Dubois","year":"2019","journal-title":"Phytomedicine."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.02173\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T05:28:21Z","timestamp":1598419701000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.02173\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,26]]},"references-count":62,"alternative-id":["10.3389\/fimmu.2020.02173"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.02173","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,26]]},"article-number":"2173"}}